Krystof, V. and S. Uldrijan. Cyclin-dependent kinase inhibitors as anticancer drugs. Curr Drug Targets[J]. 2010,11(3): 291-302.
[2]
Malumbres, M., E. Harlow, T. Hunt, et al. Cyclin-dependent kinases: a family portrait. Nat Cell Biol[J], 2009. 11(11): 1275-1276.
[3]
Zhao, H., X. Chen, M. Gurian-West, et al. Loss of cyclin-dependent kinase 2 (CDK2) inhibitory phosphorylation in a CDK2AF knock-in mouse causes misregulation of DNA replication and centrosome duplication. Mol Cell Biol[J]. 2012，32(8): 1421-1432.
[4]
Li, N., X. Zhong, X. Lin, et al. Lin-28 homologue A (LIN28A) promotes cell cycle progression via regulation of cyclin-dependent kinase 2 (CDK2), cyclin D1 (CCND1), and cell division cycle 25 homolog A (CDC25A) expression in cancer. J Biol Chem[J]. 2012,287(21): 17386-17397.
[5]
Diril, M.K., C.K. Ratnacaram, V.C. Padmakumar, et al. Cyclin-dependent kinase 1 (Cdk1) is essential for cell division and suppression of DNA re-replication but not for liver regeneration. Proc Natl Acad Sci U S A[J]. 2012,109(10): 3826-3831.
[6]
Malumbres, M. and M. Barbacid. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer[J], 2009. 9(3): 153-166.
[7]
Horiuchi, D., N.E. Huskey, L. Kusdra, et al. Chemical-genetic analysis of cyclin dependent kinase 2 function reveals an important role in cellular transformation by multiple oncogenic pathways. Proc Natl Acad Sci U S A[J]. 2012,109(17): E1019-1027.
